Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024Journal of Personalized MedicineOpen Access

Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

DVDamir VučinićUniversity of RijekaISIva SkočilićUniversity of RijekaMGMarin GolčićUniversity Hospital Centre Zagreb

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vučinić et al. (2024) studied this question.

synapsesocial.com/papers/68e764b2b6db6435876dac04https://doi.org/10.3390/jpm14030278
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor.2025
  2. 2Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma2024 · 11 citations
  3. 3Impact of age on immune-related toxicities and survival in non–small cell lung cancer treated with immune checkpoint inhibitors: A multicenter retrospective study.2026
  4. 4Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC2025 · 7 citations
  5. 5Efficacy of immunotherapy in older patients with triple-negative breast cancer: a systematic review2025